Results
Difference in change in crying or fussing duration from baseline between placebo and probiotic groups. The search identified 282 abstracts, of which 4 double-blind randomized controlled trials (345 patients, 171 placebo and 174 probiotic) met the inclusion criteria. [2] [3] [4] [5] All studies used the same probiotic, manufactured by the same company and given at the same dose, and the same placebo. All trials included breastfed infants with colic, whereas only one trial included formula-fed infants with (Table) . In subgroup analysis, the duration of crying or fussing was decreased in the breastfed infants at all time points but not in the
METHODS

DATA SOURCES
The authors searched PubMed, MEDLINE, EMBASE, the Cumulative Index of Nursing and Allied Health Literature, the Database of Abstracts of Reviews of Effects, and the Cochrane Central Register of Controlled Trials through December 2014. They also searched electronic abstracts from the Pediatric Academic Societies meetings, reference lists from articles, and nonpeer-reviewed articles through Internet searches.
STUDY SELECTION
Articles were selected through the use of an individual participant data meta-analysis. Studies were eligible for inclusion if they were doubleblind randomized controlled trials of the probiotic L reuteri DSM 17938 versus a placebo, delivered orally to infants with colic. Outcomes had to include infant crying or fussing duration. Colic was defined by the modified Wessel's criteria of crying: greater than 3 hours per day for greater than or equal to 3 days per week. 1 The primary outcome was treatment success, defined as greater than or equal to 50% reduction in crying or fussing from formula-fed infants. There were no adverse events reported in the 4 studies.
Commentary
Infant colic, or excessive infant crying of unknown cause, affects approximately 1 in 5 infants younger than 3 months. 6 It has been found to increase the risk of abusive shaking 7 and maternal depression 8 and decrease breastfeeding duration. 9 There are limited management options. However, probiotics have been proposed as possible treatments after studies revealed gut microbiota to be different between infants with and without colic [10] [11] [12] [13] and randomized controlled trials demonstrated improvement with L reuteri DSM 17938. This metaanalysis found that L reuteri DSM 17938 reduced crying or fussing duration in breastfed infants.
This meta-analysis has limitations, most notably the inclusion of only 4 randomized clinical trials with a total of 345 patients. Across the various studies and results, the most striking differences include feeding type (breastfed versus formula fed), definitions of infant colic, and outcome measurement. The collection of data was not standardized across the included studies, with only 2 of the studies using a validated diary, thereby potentially confounding the results in the studies that did not use a validated data collection tool. This is particularly important in a study in which the data collected are based on parental determination of infant crying or fussing duration in a stressful environment, leading to potential recall bias. In addition, only 2 of the included studies provided a clear definition for fussiness (described as sporadic vocalizations and nonrhythmic motor activity), leaving room for interpretation by parents. Finally, although the authors adjusted for some confounding factors, there are a number of other confounding factors that were not controlled across subgroups, including but not limited to proton-pump inhibitor exposure, hypoallergenic formula exposure, maternal dairyelimination diet, infant sleep duration, and stool colonization. It is possible that these factors alter the gut microbiome of infants and thereby affect the probiotic's effectiveness.
Overall, this meta-analysis demonstrates a potentially useful treatment for infant colic, most notably in the breastfed infant. Further research is needed to gather information on the effects of the probiotic on formula-fed and breastfed infants because their gut microbiomes are known to have different compositions. [10] [11] [12] [13] In addition, a robust randomized controlled trial with an increased sample size and strict standardization across the subgroups is necessary to better characterize the efficacy of L reuteri DSM 17938 in the treatment of infant colic.
